Pro-Dex (PDEX) Q1 2027 earnings review
Pro-Dex factory profit rises, but higher overhead limits the gain
Pro-Dex, a maker of powered surgical tools, widened its factory margins while overhead costs ate up most of the gain. Sales from businesses owned a year ago grew 8% by our math, and operating profit rose 13% even though net income fell on smaller investment gains. Chief executive Richard L. Van Kirk said the group plans to ship test units to Zimmer Biomet later this year.
| Sales from businesses owned a year ago | +8.2% 11.0% reported growth ($20.6M) |
|---|---|
| Gross margin | 33.4% +4.4 percentage points from a year ago |
| Operating income | $3.5M +13.1% from a year ago |
| Zimmer Biomet validation units | New expected to ship later in FY27 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because higher engineering and office costs matched the improvement in gross margin. Sales of its newer surgical handpiece to its largest customer mostly replaced lost repair work on the older model, leaving total revenue near last quarter's level. One bright spot: collecting overdue customer bills cut net debt by more than half.
The question now is whether internal engineering projects and the Zimmer Biomet partnership can start a new wave of sales before growth at its top customer levels off. Either new products lift revenue past the current plateau, or higher research and administrative payroll squeezes operating profit. Second-quarter medical device sales and engineering spending will tell.
🐂 Bull Case
New Handpiece Sales Lift Gross Margin
Pro-Dex designs and manufactures powered surgical tools for medical device distributors. A year ago, tariff costs squeezed its profitability, because the company could not pass all of those duties on to buyers. This quarter, gross margin rose 4.4 percentage points to 33.4% on "favorable product mix", Pro-Dex said.
Cost of sales — the direct cost of making its surgical tools — fell from 71.0% of revenue to 66.6% by our math. Medical device sales grew by $3.3 million, led by $1.8 million more of its newer surgical handpiece for its largest customer. Selling more newly manufactured tools and doing fewer repairs on the older model lifted the margin on every dollar of sales.
What to watch: gross margin in the second quarter. Staying above 33% would show that higher prices and in-house parts production are keeping ahead of component costs.
Operating Profit Rises Despite Investment Gain Drop
Headline net income fell 35% from a year ago to $3.0 million, and diluted profit per share dropped from $1.40 to $0.92. That drop had nothing to do with selling surgical tools. A year ago, Pro-Dex booked a $3.3 million paper gain on shares it held in Monogram Technologies, a surgical robotics firm that Zimmer Biomet later bought for cash.
This quarter, paper gains on investments totaled $73,000, the company said. Stripping out those investment swings on both sides, pre-tax profit grew 13.1% to $3.3 million by our math, matching the 13.1% rise in operating income.
What to watch: operating income growth in the second quarter. It gives a clean reading on the medical device business without noise from the investment portfolio.
Customer Collections Cut Net Debt in Half
Pro-Dex ended last fiscal year with $21.2 million in unpaid customer bills, equal to a full quarter of sales. Over the past three months, the surgical tool maker collected $3.7 million of that balance, bringing accounts receivable down 17.4% from last quarter to $17.5 million.
Those collections lifted total cash and marketable investments by $3.6 million to $13.0 million, while management paid down $1.0 million of debt. By our math, net debt — total debt minus cash and short-term investments — fell 57.5% in three months, from $8.1 million to $3.5 million.
What to watch: accounts receivable and operating cash flow in the second-quarter filing. Further collections would leave the balance sheet nearly debt-free on a net basis.
🐻 Bear Case
Old Handpiece Repairs Eat Into New Sales
"We are pleased with our first quarter results and continued top line revenue growth," chief executive Richard L. Van Kirk said. Reported sales grew 11.0% to $20.6 million. Strip out $511,000 from Advanced Precision Machining (APM), a machine shop acquired in February 2026, and sales from businesses owned a year ago grew 8.2% by our math.
- Newer surgical handpiece sales to top customer: up $1.8 million from a year ago
- Older handpiece repair revenue from that customer: down $1.7 million
- Total sales compared with last quarter: up 0.8% by our math
A year ago, shipments of the newer handpiece reached the customer's requested recurring level. Now that Pro-Dex laps that ramp, new handpiece sales barely outpace the drop in repairs on the retired model, so total revenue has stayed near $20.5 million for two straight quarters.
What to watch: medical device revenue outside the largest customer next quarter. Without another product ramp, quarterly sales will struggle to move above the current $20.6 million mark.
Rising Overhead Eats Most of the Margin Gain
Pro-Dex expanded its gross margin by 4.4 percentage points from a year ago, yet its operating margin barely moved, rising 0.3 points to 17.1% by our math. Higher overhead and research bills absorbed almost all of the factory improvement. Total operating expenses rose 48.0% to $3.3 million, taking 4.1 points more of revenue.
Selling, general and administrative costs — overhead and office pay — rose 2.3 points of revenue to 10.4% by our math, on $466,000 from running APM and $195,000 more for "accounting, mergers and acquisitions, human resources, and information technology", the company said. Research and development costs rose 1.7 points of revenue to 5.9% on "personnel costs as well as higher internal project expenditures". Even without APM, operating expenses grew 27.4% by our math.
What to watch: research and development spending next quarter. If project costs stay elevated before new tools ship, operating margin will remain capped near 17%.
👓 Other Themes
Machine Shop Acquisition Adds More In-House Parts
In February 2026, Pro-Dex bought APM, a local supplier that makes parts for aerospace, defense and medical devices. This quarter, the unit brought in $511,000 of outside sales and $466,000 of separate operating costs, the company said. It also supplied $814,000 of machined components to Pro-Dex itself, which are removed from consolidated revenue but keep more manufacturing work in-house.
💲 Other KPIs
Stockpiles of raw parts and finished surgical tools rose 2.1% from last quarter and 1.6% from a year ago by our math. Inventory has stayed between $21.5 million and $22.4 million for five straight quarters, tying up cash even as sales grew 11.0% over the past year.
The average number of diluted shares fell 0.7% from a year ago by our math, as earlier buybacks offset employee stock awards. Compared with last quarter, the diluted share count rose 0.6%, from 3.29 million to 3.32 million.
🔮 Guidance
New. Pro-Dex does not issue dollar revenue or profit targets. Chief executive Richard L. Van Kirk said the company is working with Monogram and its new owner, orthopedic group Zimmer Biomet, and expects to ship test units later this fiscal year (ending June 2027). Those shipments are an engineering step toward commercial manufacturing rather than an immediate revenue driver.
❓ Key Questions
When could Zimmer Biomet test units turn into commercial orders?
Pro-Dex plans to ship validation units to Monogram and Zimmer Biomet later this fiscal year. Investors need to know how long regulatory and customer testing will take before commercial production could begin.
How much further can older handpiece repair revenue fall?
Repairs on the older handpiece for Pro-Dex's largest customer fell $1.7 million from a year ago, after dropping $6.0 million across all of last fiscal year. Management has not disclosed how much quarterly repair revenue remains to fade.
Why is inventory still near $22 million after the ramp?
Pro-Dex built inventory past $22 million while ramping up its newest orthopedic handpiece. Shipments reached steady levels a year ago, yet inventory still equals more than a full quarter of revenue.